

Table S2. Discrepant recommendations of cancer genomic tests between organizations, by order of statement issuance

Test	Purpose	First recommendation statement			Second recommendation statement			Third recommendation statement			Fourth recommendation statement			
		Year	Source	Category ^a	Year	Source	Category ^a	Year	Source	Category ^a	Year	Source	Category ^a	
BRAF	Pharmacogenomic for anti-EGFR therapy in colon cancer	2011	NCCN	2	2013	NCCN	2							
						EGAPP	3							
CYP2D6	Pharmacogenomic for tamoxifen use in breast cancer	2005	ASCO	3	2010	NCAB	2		2011	BCBS	3			
						ASCO	3			AHS	3			
ERRC1	Prognostic / Pharmacogenomic use in NSCLC	2009	ASCO	- / 3	2011	NCCN	- / 3		2013	NCCN	2 / 2			
Oncotype DX	Prognostic / Pharmacogenomic use in lymph node-negative, ER-positive breast cancer	2007	ASCO	2 / 2	2009	NACB	1 / 2		2011	NCCN	2 / 2	2013	NICE	1 / 1
						EGAPP	- / 3							
RRM1	Prognostic / Pharmacogenomic use in NSCLC	2009	ASCO	- / 3	2010	NCCN	2 / 2		2011	NCCN	2 / 2			
UGT1A1	Pharmacogenomic use for irinotecan dosing in colon cancer	2009	EGAPP	3	2010	NCAB	2							

^a The - symbol indicates that the corresponding organization did not comment on the tests' prognostic purpose.